Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

Here’s how Bio-Gene is keeping your muesli bug free

  • In News
  • March 7, 2022
  • Samantha Freidin
Here’s how Bio-Gene is keeping your muesli bug free

The range of creepy crawlies that find their way into Australian grain stores is broad enough to make you rethink your morning oats. I mean, no one likes the taste of flour beetles or weevils in their brekkie.

Agricultural technology development company Bio-Gene Technology (ASX: BGT) agrees, and are working on solutions to common pests in stored grain. 

The Company recently ran a 9 month trial wherein they utlised their combination pesticide treatment in the field to evaluate its efficacy. Flavocide is Bio-Gene’s proprietary insecticide that works via a unique mechanism of action. The program proved effective with Bio-Gene’s formula performing well, controlling five common grain pests: the Lesser grain borer, Flour beetle, Saw-toothed grain beetle, Flat grain beetle and Rice weevil.

Following the results of the initial study, follow up assessments were conducted 6 and 9 months after treatment. The final results showed that the combination insecticide treatment controlled non-resistant strains of all species, and resistant strains in three of the five target species. 

“Given these results, Bio-Gene is progressing discussions on the development program including next steps towards product development and registration,” said Richard Jagger, CEO of Bio-Gene. 

“The results of this longer-term study demonstrate the effectiveness of Flavocde in combination with other chemistry groups. The successful control of all susceptible strains of all five species tested over the 9-month study period is a great outcome. Control of resistant strains of all five species for either the full 9 months or a shorter period is very positive. Together with previous Flavocide efficacy testing results, this result forms the basis for Flavocide product label recommendations for control of the major pest species impacting grain storage.”

Another Flavocide study led by The Department of Agriculture and Fisheries in Queensland reported upon conclusion that the insecticide was effective against the Lesser grain borer in grain types other than wheat (namely maize and barley). 

Pesticides and crop protection in Australia is big business with their 2019 sales value being over $1.5 billion dollars. 

The market is dominated by a few key players however, there is plenty of room for innovation with changing climate conditions, technological advancements and growing resistance to commercially available pesticides. 

Currently there is no available single chemistry solution that controls all major pests in stored grain. Adding to the challenge is the increase in pest resistance which ultimately results in larger product losses for growers.  Flavocide is a potential remedy to resistant pests thanks to its novel mode of action, reducing the risk of further insecticide resistance moving forwards. 

For the half year ended 31st December 2021, Bio-Gene reported a 360% increase in revenue compared to the previous year. A $3.2 million capital raise in December saw the Company round out the period with $5.8 million cash at hand. 

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • bio-gene
  • flavocide
  • grain insects
  • insecticide
  • richard jagger
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.